Healthy
Conditions
Brief summary
Objective: Primary objective of the present study was to compare the single dose bioavailability of Torrent's Rabeprazole Sodium Delayed Release Tablets 20 mg and Aciphex® Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA). Dosing periods were separated by a washout period during fed study. Study Design: Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study
Interventions
Sponsors
Torrent Pharmaceuticals Limited
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male human volunteers within the age range of 18 to 50 years * A body mass index within 18-25 Kg/m2 * Given written informed consent to participate in the study * Absence Of disease markers of HIV 1& 2, hepatitis B & C virus and RPR. * Absence of significant disease or clinically' significant abnormal laboratory values on laboratory evaluation, medical history and medical examination during the screening * A normal 12 lead ECG. * A normal chest X-ray (FA view) * Comprehension of the nature and purpose'of the study and compliance with the requirement of the entire protocol * No history or no evidence of hypersensitivity to rabeprazole substituted benzimidazoles or to any component of the formulation * No history of Anaphylaxis arid Angioedema * No history or presence of gastric malignancy * No history of significant systemic diseases * No history of psychiatric disorders * No history of addiction to any recreational drug or drug dependence * No donation of blood(one unit or 350 mL) within 90 days prior to study check-in * No participation in any clinical study within the last 90 days * No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations' vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in * No history of dehydration from diarrhea, vomiting or any other reason within a period of 24.0 hours prior to study check-in * No family history of neurological disorders * Not consumed alcohol and xanthin containing food and beverages, (chocolates, tea,coffee or cola drinks) cigarettes and tobacco products for at least 48.0 hours prior to study check-in for each period. * Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Cannabinoids and Barbiturates) in urine during the day of study check-in of each period * Not consumed grapefruit(mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in * Negative alcohol breath analysis during the study check-in of each period
Exclusion criteria
* History of seizures * Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study * History of alcohol consumption for more than two units/day (1 unit=30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48.0 hours prior to check-in * High caffeine (more than 5 cups of coffee or tea/day) or tobacco (mote than 9 cigarettes/beedies/cigars per day) consumption * History of difficulty with donating blood or difficulty in accessibility of veins * An unusual or abnormal diet for whatever reason e.g. because of fasting due to religious reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| bioequivalence based on Composite of Pharmacokinetics | plasma samples were obtained from blood drawn at Pre-dose and 0.5, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 8.00, 10.00, 12.00, 14.00, 18.00 and 24.00 hours after dose administration | bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax. |
Countries
India
Outcome results
None listed